Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common shares, Euro 0.12 nominal value per share
-
Shares outstanding
-
26,019,256
-
Total 13F shares
-
7,995,442
-
Share change
-
-58,689
-
Total reported value
-
$35,178,298
-
Price per share
-
$4.40
-
Number of holders
-
16
-
Value change
-
-$409,463
-
Number of buys
-
3
-
Number of sells
-
6
Institutional Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q1 2022
As of 31 Mar 2022,
LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,995,442 shares.
The largest 10 holders included
Novo Holdings A/S, Redmile Group, LLC, Nicholas Investment Partners, LP, Nantahala Capital Management, LLC, AXA S.A., Artal Group S.A., MILLENNIUM MANAGEMENT LLC, DAFNA Capital Management LLC, Alpha Wave Global, LP, and Point72 Asset Management, L.P..
This page lists
16
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.